120 related articles for article (PubMed ID: 12817764)
1. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?
Brody BA; Dickey N; Ellenberg SS; Heaney RP; Levine RJ; O'Brien RL; Purtilo RB; Weijer C
J Bone Miner Res; 2003 Jun; 18(6):1105-9. PubMed ID: 12817764
[TBL] [Abstract][Full Text] [Related]
2. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.
Rosenblatt M
J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772
[TBL] [Abstract][Full Text] [Related]
3. Is it ethical to use placebos in osteoporosis trials?
Ragi-Eis S; Zerbini CA; Provenza JR; Griz LH; de Gregório LH; Russo LA; Silva NA; Borges JL; de Souza AC; Castro ML; Lewiecki EM
J Clin Densitom; 2006; 9(3):274-80. PubMed ID: 16931344
[TBL] [Abstract][Full Text] [Related]
4. Study design in osteoporosis: a European perspective.
Kanis JA; Alexandre JM; Bone HG; Abadie E; Brasseur D; Chassany O; Durrleman S; Lekkerkerker JF; Caulin F
J Bone Miner Res; 2003 Jun; 18(6):1133-8. PubMed ID: 12817770
[TBL] [Abstract][Full Text] [Related]
5. Placebo controls in clinical trials of new therapies for osteoporosis.
Levine RJ
J Bone Miner Res; 2003 Jun; 18(6):1154-9. PubMed ID: 12817775
[No Abstract] [Full Text] [Related]
6. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
Polman CH; Reingold SC; Barkhof F; Calabresi PA; Clanet M; Cohen JA; Cutter GR; Freedman MS; Kappos L; Lublin FD; McFarland HF; Metz LM; Miller AE; Montalban X; O'Connor PW; Panitch H; Richert JR; Petkau J; Schwid SR; Sormani MP; Thompson AJ; Weinshenker BG; Wolinsky JS
Neurology; 2008 Mar; 70(13 Pt 2):1134-40. PubMed ID: 18362273
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF).
Silverman SL; Cummings SR; Watts NB;
J Bone Miner Res; 2008 Jan; 23(1):159-65. PubMed ID: 17892379
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
Cortet B
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
[TBL] [Abstract][Full Text] [Related]
9. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
Pak CY; Adams-Huet B; Sakhaee K; Bell NH; Licata A; Johnston C; Rubin B; Bonnick S; Piziak V; Graham H; Ballard J; Berger R; Fears W; Breslau N; Rubin C
J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339
[TBL] [Abstract][Full Text] [Related]
10. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
Gordon PH
Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
[TBL] [Abstract][Full Text] [Related]
11. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Daugherty CK; Ratain MJ; Emanuel EJ; Farrell AT; Schilsky RL
J Clin Oncol; 2008 Mar; 26(8):1371-8. PubMed ID: 18227527
[TBL] [Abstract][Full Text] [Related]
12. [Placebo in clinical research--a continual compromise between ethical requirements and scientific rigor].
Saccà L
Ann Ital Med Int; 2002; 17(4):215-20. PubMed ID: 12532559
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
14. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
15. [Placebo-controlled trials in schizophrenia].
Melamed Y; Davidson M; Bleich A
Harefuah; 2004 Mar; 143(3):236-40, 244. PubMed ID: 15065367
[TBL] [Abstract][Full Text] [Related]
16. Study designs in osteoporosis.
Temple RJ
J Bone Miner Res; 2003 Jun; 18(6):1129-32. PubMed ID: 12817769
[No Abstract] [Full Text] [Related]
17. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
Siminoski K; Josse RG
CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
[TBL] [Abstract][Full Text] [Related]
18. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
[TBL] [Abstract][Full Text] [Related]
19. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.
McCloskey EV; Beneton M; Charlesworth D; Kayan K; deTakats D; Dey A; Orgee J; Ashford R; Forster M; Cliffe J; Kersh L; Brazier J; Nichol J; Aropuu S; Jalava T; Kanis JA
J Bone Miner Res; 2007 Jan; 22(1):135-41. PubMed ID: 17042717
[TBL] [Abstract][Full Text] [Related]
20. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Martens MG
J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
